View Article

28
Ashland, Ky.— Urologists at King’s Daughters Medical Center are now providing patients with advanced stage prostate cancer a customized treatment that stimulates a patient’s own immune system to fight the disease.

 
The treatment, Provenge®, is the only Food and Drug Administration approved immunotherapy for some men with advanced prostate cancer. The treatment uses the patient’s own immune system to identify and target prostate cancer cells. Each dose is manufactured specifically for each patient using his own immune cells.

 
Provenge is not a chemotherapy drug and is different from hormone therapy, which decreases the level of testosterone in the body. A typical Provenge course of treatment can be completed in about a month, and the most common side effects are primarily mild or moderate.

 
Individuals interested in learning whether Provenge may be a treatment option can call King’s Daughters Medical Specialties — Urology at (606) 324-4404. The practice includes urologists William Boykin, M.D., Timothy Dixon, M.D., James M. Krick, D.O., and Charles Thorndyke, M.D. 

 
According to the American Cancer Society, prostate cancer is the second-most common cancer in men in the U.S. and the second-leading cause of cancer-related deaths in men. One in six men will be diagnosed with prostate cancer during his lifetime, and one in 36 will die from the disease.

 
KDMC is a locally-controlled, not-for-profit, 465-bed regional referral center, offering comprehensive cardiac, vascular, medical, surgical, maternity, pediatric, rehabilitative, psychiatric, cancer, neurological, pain care, wound care and home care services. For additional information, visit us online at kdmc.com or call 1-877-377-KDMC (5362).

Post Rating

Comments

There are currently no comments, be the first to post one.

Post Comment

Name (required)

Email (required)

Website

CAPTCHA image
Enter the code shown above: